Janus Henderson Group PLC Cuts Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Janus Henderson Group PLC reduced its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 27.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 863,846 shares of the company's stock after selling 324,345 shares during the period. Janus Henderson Group PLC owned 1.59% of Bicara Therapeutics worth $15,009,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Deutsche Bank AG acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $1,959,000. DAFNA Capital Management LLC purchased a new stake in Bicara Therapeutics in the 4th quarter valued at $1,838,000. Deep Track Capital LP increased its stake in shares of Bicara Therapeutics by 151.0% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock worth $34,840,000 after acquiring an additional 1,203,148 shares during the last quarter. Braidwell LP raised its holdings in shares of Bicara Therapeutics by 20.7% during the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company's stock worth $34,851,000 after acquiring an additional 343,059 shares during the period. Finally, Blackstone Inc. raised its holdings in shares of Bicara Therapeutics by 40.5% during the 4th quarter. Blackstone Inc. now owns 913,060 shares of the company's stock worth $15,906,000 after acquiring an additional 263,060 shares during the period.

Bicara Therapeutics Trading Down 2.3%

BCAX stock traded down $0.34 during mid-day trading on Thursday, hitting $14.25. 159,299 shares of the company were exchanged, compared to its average volume of 489,289. Bicara Therapeutics Inc. has a 12-month low of $8.91 and a 12-month high of $28.09. The business has a fifty day simple moving average of $12.93 and a 200-day simple moving average of $15.13.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BCAX. Wedbush reissued an "outperform" rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday. Wells Fargo & Company began coverage on shares of Bicara Therapeutics in a research note on Thursday, April 17th. They issued an "underweight" rating and a $8.00 price target for the company. HC Wainwright reduced their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.